|
Regenerative Medicine: A New Frontier for Therapeutic Intervention
11th March 2010 |
|
| Programme: | |
| 09.30 | Arrival, Registration and Coffee |
| 09.55 | Opening announcements |
| Session 1 - Chair: Dr. Wendy Alderton | |
| 10.00 |
Dr Stephen Minger, Global Director R&D
Cell Technologies, GE Healthcare, UK Historical Perspective on Stem Cell Research |
| 10.45 |
Professor Austin Smith , Wellcome
Trust Centre for Stem Cell Research, Cambridge University, UK Fundamental Biology of Stem Cells |
| 11.30 |
Professor Peter Coffey, Institute of
Ophthalmology, University College London, UK Retinal pigmented epithelial cell therapy for the treatment of age related macular degeneration |
| 12.15 | Lunch |
|
Session 2 - Chair: Dr Richard Davenport |
|
| 13.15 |
Dr Mark Bunnage, Head of Chemistry,
Pfizer Regenerative Medicine, UK Small molecule approaches for modulation of stem cell activity |
| 14.30 |
Dr. Paul Kemp, CSO & Founder,
Intercytex Ltd, UK Perspective on the challenges of conducting clinical trials in regenerative medicines |
| 15.15 | Tea |
| Session 3 - Chair: Dr Ruth McKernan | |
| 15.45 |
Dr Eduardo Bravo, CEO of Cellerix, Spain |
| 16.30 |
Dr Koenraad Blot,
CMO of TiGenix, Belgium The making of ChondroCelect: clinical and regulatory successes and challenges |
| 17.15 | Closing remarks and thanks – SMR Chairman |
| Home / Meetings / Membership / Student Bursaries / Administration / History of the SMR / SMR Award / Archive Material / Links / Contact Us |